^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | RNK07421 (HSP90 degrader, KRAS G12C degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB231 / 6 - Overcoming KRAS G12C inhibitor resistance with a chaperone-mediated protein degrader (CHAMP)
Published date:
03/15/2023
Excerpt:
Treatment of adagrasib-resistant NSCLC cells and PDOs with RNK07421 resulted in decreased levels of KRAS G12C, p-ERK and RTKs. Furthermore, in vivo treatment with RNK07421 demonstrated dramatic tumor growth inhibition as compared to adagrasib treatment alone. Together, these observations indicate that the novel mechanisms of action of RNK07421 may provide several advantages over G12C inhibitors and possibly other targeted protein degradation agents to effectively treat KRAS G12C-dependent NSCLC.